ACR Image Metrix hires Kathy Freeman

As business development manager for the US East Coast

ACR Image Metrix, a global imaging contract research organisation (CRO) based in the American College of Radiology Clinical Research Center in Philadelphia, US, has welcomed Kathy Freeman as business development manager for the East Coast of the US.

Freeman has extensive experience in sales strategies, team leadership and new market development.

Prior to joining ACR Image Metrix, Freeman held key positions within niche CRO organisations, where she landed numerous contracts in the pharmaceutical and biotech market. She began her career selling specialist pharmaceuticals.

ACR Image Metrix provides imaging CRO services to assist pharmaceutical, biotech and medical device companies around the world.

You may also like

Manufacturing

25 years of Guardtech: Isopod Manufacturing Director Michael Burton Q&A

One of the Group’s longest-serving superstars gives his thoughts on why the Guardtech Group are pushing the boundaries of small-scale cleanroom provision with their rapid-assembly pod systems
Research & Development

Genentech provides update on Astegolimab in chronic obstructive pulmonary disease

Pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every 2 weeks
Manufacturing

Aenova expands Killorglin site with spray drying platform

New equipment to help overcome bioavailability hurdles and accelerate time-to-market
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Precision under pressure

Why pharma manufacturing needs a harder look at weight control
Research & Development

Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacy outcome and expansion to larger global patient studies
Subscribe now